Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2′-deoxycytidine by targeting miR-9

被引:2
|
作者
Li, F. [1 ]
He, W. [1 ]
Geng, R. [1 ]
Xie, X. [1 ]
机构
[1] Tongji Univ, Sch Med, Dept Pediat, Tongji Hosp, 389 Xincun Rd, Shanghai 200065, Peoples R China
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2020年 / 22卷 / 01期
关键词
Myeloid Leukemia; EVI1; 5-Aza-2 '-deoxycytidine; miR-9; Methylation; PROGNOSTIC-SIGNIFICANCE; OVEREXPRESSION; MYELOPOIESIS; RESISTANCE; MICRORNAS; CANCER; GENE; DNA;
D O I
10.1007/s12094-019-02121-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose High expression of ecotropic viral integration site 1 (EVI1) has been associated with a poor prognosis in leukemia patients, but the underlying mechanism remains unclear. Aberrant expression of microRNAs plays critical roles in leukemia development. MiR- 9 is a putative potential target of EVI1. We have investigated the regulating mechanism of miR-9 by EVI1 in leukemia cells. Methods We first examined the relationship between miR-9 and EVI1 expression levels in nine leukemia cell lines by RTPCR. Then we forced high expression of EVI1 in UoCM1 and K562 cells to confirm the downregulation of miR-9 by EVI1. Methylation of the miR-9 promoter region was detected by DNA bisulfite sequencing. We treated the EVI1-overexpressing cells with the hypomethylating agent 5-aza-2'-deoxycytidine (5-AZA) to reverse EVI1-induced hypermethylation of miR-9. Results EVI1 and miR-9 expression was negative related. Forced expression of EVI1 downregulated miR-9 by inducing hypermethylation of the miR-9 promoter. 5-AZA reversed high EVI1- induced hypermethylation of the miR-9 promoter and restored the expression of miR-9. 5-AZA induced extensive apoptosis and inhibited proliferation through cell cycle arrest in EVI1-overexpressing leukemia cells. Conclusions Our results suggest that EVI1 may be involved in leukemia cell proliferation and apoptosis via the regulation of miR-9 promoter methylation. 5-AZA may represent a promising therapeutic option for EVI1-high leukemia patients.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 50 条
  • [21] Analysis of EVI1 Gene Expression in Acute Myeloid Leukemia Patients in the Northeast of Iran
    Sadeghian, Mohammad-Hadi
    Ayatollahi, Hosein
    Shams, Seyyede-Fatemeh
    Dezaki, Zahra Rezaei
    MIDDLE EAST JOURNAL OF CANCER, 2019, 10 (04) : 305 - 313
  • [22] DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia
    Yang, Allen S.
    Doshi, Ketan D.
    Choi, Sang-Woon
    Mason, Joel B.
    Mannari, Rajan K.
    Gharybian, Vazganush
    Luna, Rene
    Rashid, Asif
    Shen, Lanlan
    Estecio, Marcos R. H.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Issa, Jean-Pierre J.
    CANCER RESEARCH, 2006, 66 (10) : 5495 - 5503
  • [23] EVI1 expression,clinical and cytogenetical characteristics in 447 patients with acute myeloid leukemia
    何雪峰
    China Medical Abstracts(Internal Medicine), 2017, 34 (01) : 55 - 56
  • [24] Epigenetic therapy of acute myeloid leukemia using 5-aza-2′-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
    Momparler, Richard L.
    Cote, Sylvie
    Momparler, Louise F.
    Idaghdour, Youssef
    CLINICAL EPIGENETICS, 2014, 6
  • [25] 5-Aza-2′-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis
    Valdez, Benigno C.
    Li, Yang
    Murray, David
    Corn, Paul
    Champlin, Richard E.
    Andersson, Borje S.
    LEUKEMIA RESEARCH, 2010, 34 (03) : 364 - 372
  • [26] INVITRO AND INVIVO EFFECTS OF 5-AZA-2'-DEOXYCYTIDINE (DECITABINE) ON CLONOGENIC CELLS FROM ACUTE MYELOID-LEUKEMIA PATIENTS
    GATTEI, V
    ALDINUCCI, D
    PETTI, MC
    DAPONTE, A
    ZAGONEL, V
    PINTO, A
    LEUKEMIA, 1993, 7 : 42 - 48
  • [27] 5-AZA-2'-DEOXYCYTIDINE AS A DIFFERENTIATION INDUCER IN ACUTE MYELOID LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES OF THE ELDERLY
    PINTO, A
    ZAGONEL, V
    ATTADIA, V
    BULLIAN, PL
    GATTEI, V
    CARBONE, A
    MONFARDINI, S
    COLOMBATTI, A
    BONE MARROW TRANSPLANTATION, 1989, 4 : 28 - 32
  • [28] CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression
    Y Saito
    S Nakahata
    N Yamakawa
    K Kaneda
    E Ichihara
    A Suekane
    K Morishita
    Leukemia, 2011, 25 : 921 - 931
  • [29] CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression
    Saito, Y.
    Nakahata, S.
    Yamakawa, N.
    Kaneda, K.
    Ichihara, E.
    Suekane, A.
    Morishita, K.
    LEUKEMIA, 2011, 25 (06) : 921 - 931
  • [30] Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
    Richard L Momparler
    Sylvie Côté
    Louise F Momparler
    Youssef Idaghdour
    Clinical Epigenetics, 2014, 6